Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by tissue testing) with advanced, spreading, or returning ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that cannot be cured.
• People whose cancer came back or got worse within six months of finishing a platinum-based chemotherapy treatment (this is called "platinum-resistant" disease).
• People who have cancer that can be seen and measured on scans or physical examination, with all imaging done within 28 days before joining the trial.
• People whose cancer tumours meet specific size requirements on scans or physical examination (confirm with trial site for exact measurements).
• People who are 18 years of age or older.
• People who are well enough to carry out light daily activities — rated 0, 1, or 2 on a standard health and activity scale used by doctors (confirm with trial site).
• People who have had at least one prior round of chemotherapy that included a platinum drug, with any number of prior treatments overall permitted. Prior immunotherapy, hormone therapy, or PARP inhibitor therapy is also acceptable.
• People who have never previously received a type of drug that blocks blood vessel growth (anti-angiogenesis therapy), including a drug called bevacizumab.
• People for whom a BC Cancer "Compassionate Access Program" approval has been granted before treatment starts.
• People who have had prior radiation therapy, provided at least 28 days have passed since the last radiation dose before starting treatment (exceptions may apply for low-dose radiation — confirm with trial site).
• People who have had prior surgery, provided at least 28 days have passed since the surgery, and wounds have fully healed.
• People of childbearing potential who have agreed to use highly effective contraception during the study and for up to 5 months after the last treatment dose.
• People who are able to give informed consent by signing a consent form before the study begins (or whose legal guardian or representative can sign on their behalf if they are physically unable to do so).
• People who are able to attend all treatments and follow-up appointments at the participating trial centre.

Who may not be able to join:

• People who currently have another active cancer that requires treatment.
• People with serious medical or mental health conditions that could be made worse by treatment or that would make it difficult to follow the study requirements, including uncontrolled high blood pressure or an active, uncontrolled infection.
• People who are currently receiving other cancer treatments or are taking part in another clinical trial involving investigational treatments.
• People whose neutrophil count (a type of white blood cell) is below a certain level, indicating low immune function (confirm exact threshold with trial site).
• People who are pregnant or breastfeeding.
• People with a bleeding disorder.
• People with a history of bowel obstruction, or a current unresolved bowel obstruction.
• People with uncontrolled blood clots in arteries or veins (note: if the condition becomes controlled, eligibility may still be possible — confirm with trial site).
• People who have had a heart attack or stroke within the past 4 months.
• People with cancer that has spread to the brain or central nervous system that has not been treated or is not under control.
• People with open wounds, wounds that are not healing, or known abnormal passages between organs (fistulas) that have not healed.

Important: Always verify eligibility with the trial site directly before applying.